The Association of MTHFR C677T and A1298C Polymorphisms with Methotrexate Response and Toxicity in Psoriasis

Authors

  • Sauvarat Auepemkiate

Keywords:

MTHFR, polymorphism, psoriasis, methotrexate

Abstract

Background: Methotrexate (MTX) is used to treat psoriasis with various side effects and responsiveness. No predictive indicator of responsiveness or toxicity is available.
Objective: To study the association of the C677T and A1298C polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene with the responsiveness and side effects of MTX in psoriatic Thai patients.
Methods: The polymorphisms were identified from 86 MTX-treated patients in three hospitals located in southern Thailand using allele-specific PCR. The patients were monitored for the effectiveness and toxicity of the MTX.
Results: The C677T genotype frequencies for C/C, C/T, and T/T were 70.9, 26.8, and 2.3%, respectively, and those of the A1298C genotypes for A/A, A/C, and C/C were 57, 32.5, and 10.5%, respectively. Seventy-three patients (87.9%) responded to MTX. The non-responders had higher combined frequencies of C/T and T/T of the C677T (50%) than the responders (24.7%) with no statistical significance (p = 0.131), but had a lower frequency of CC genotype of the A1298C, although not statistically different (p =0.691). Eleven patients (12.8%) suffered toxicity. No association of these polymorphisms and MTX toxicity was found.
Conclusion: The study did not show an association between these MTHFR polymorphisms with MTX response and toxicity in these patients.

Downloads

Published

20-10-2016

How to Cite

Auepemkiate, S. (2016). The Association of MTHFR C677T and A1298C Polymorphisms with Methotrexate Response and Toxicity in Psoriasis. Siriraj Medical Journal, 68(5), 271–276. Retrieved from https://he02.tci-thaijo.org/index.php/sirirajmedj/article/view/69326

Issue

Vol. 68 No. 5 (2016): September-October

Section

Original Article

License

Users are free to share, copy, and redistribute all articles published in the Siriraj Medical Journal (SMJ) in any medium or format as long as you follow the following terms:

  • Attribution — You must give appropriate credit, provide a link to the material, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the publisher endorses you or your use.
  • NonCommercial — You may not use the material for commercial purposes.
  • NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.